Rani Therapeutics Holdings (RANI) Cash from Operations (2020 - 2026)

Rani Therapeutics Holdings' Cash from Operations history runs 7 years deep, the most recent figure standing at 6497000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 20.27% year-over-year to 6497000.0 in Q1 2026; TTM through Mar 2026 was 17062000.0, a 50.17% increase from a year earlier, with the FY2025 full-year figure at 18714000.0, up 47.28% from the prior year.
• Cash from Operations retreated to 6497000.0 in Q1 2026 per RANI's latest filing, from 286000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 286000.0 in Q4 2025 and bottomed at 14629000.0 in Q4 2022.
• The 5-year median for Cash from Operations is 9360000.0 (2022), against an average of 9321058.82.
• Across the five-year window, Cash from Operations sank 131.23% in 2022 and soared 103.3% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 14629000.0 in 2022, then advanced by 14.7% to 12478000.0 in 2023, then jumped by 30.64% to 8655000.0 in 2024, then surged by 103.3% to 286000.0 in 2025, then slumped by 2371.68% to 6497000.0 in 2026.
• Per Business Quant, the three latest RANI Cash from Operations figures stand at 6497000.0 (Q1 2026), 286000.0 (Q4 2025), and 5100000.0 (Q3 2025).